Journal
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
Volume 122, Issue 1, Pages 9-18Publisher
ELSEVIER TAIWAN
DOI: 10.1016/j.jfma.2022.09.010
Keywords
Parkinson?s disease; Gut microbiota; Gut -brain axis; Probiotics; Live biotherapeutic; product
Categories
Ask authors/readers for more resources
Neuropathology studies have found that Parkinson's disease may originate in the gut enteric nervous system and spread to the central dopaminergic neurons through the gut-brain axis. The gut microbiomes and metabolites of PD patients have been found to be different from unaffected controls. Targeting the gut microbiota as a potential disease-modifying therapy for PD has been suggested, especially for patients whose disease begins in the gut.
Neuropathology studies have shown that the pathognomonic feature of Parkinson's disease (PD), one of the most common neurodegenerative disorders, may start from the gut enteric nervous system and then spread to the central dopaminergic neurons through the gut-brain axis. With the advent of metagenomic sequencing and metabolomic analysis, a plethora of evidence has revealed different gut microbiomes and gut metabolites in patients with PD compared with unaffected controls. Currently, although dopaminergic treatments and deep brain stimulation can provide some symptomatic benefits for motor symptoms of the disease, their long-term use is problematic. A mechanism-targeted therapy to halt the neurodegeneration is lacking. The recently observed gut microenvironmental changes in the early stages of the disease play a vital role in the PD pathogenesis. Patients whose disease begins in the gut may benefit most from interventions that target the gut microenvironments. In this review, we will summarize the current studies demonstrating multifunctional roles of gut microbiota in the gut-brain axis of PD and the currently available evidence for targeting the gut microbiota as a novel approach to potential disease-modifying therapy in PD.Copyright (c) 2022, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available